Citing patent infringement, Lipocine sues Clarus; Sangamo, DBV unveil share offerings
→ Metabolic and endocrine disorder-focused Lipocine $LPCN on Wednesday said it was suing Clarus Therapeutics for its recently approved oral testosterone replacement therapy, Jatenzo, alleging the latter has infringed on 6 its US patents. Clarus shot back, saying “When the facts are brought before the court, we are confident that Lipocine’s assertions will be found to be without merit.”
→ Riding the wave of its promising — but early stage — snapshot of its Pfizer $PFE-partnered hemophilia A gene therapy, Sangamo Therapeutics $SGMO on Wednesday said it was offering up more shares to raise funds in a public offering — the size of the offering and price per share will be revealed later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.